



***Ventripoint***  
*Diagnostics Ltd.*

---

2D Echocardiography with the

---

Accuracy of cardiac MRI

---

# ***Safe Harbour Statement***

The information in this presentation may include forward-looking statements related to our future growth, trends in our industry, our financial and or operational results, and our financial or operational performance. Such forward-looking statements are predictive in nature, and may be based on current expectations, forecasts or assumptions involving risks and uncertainties that could cause actual outcomes and results to differ materially from the forwardlooking statements themselves. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as "believes", "expects", "anticipates", "estimates", "intends", "plans", or similar expressions, or may employ such future or conditional verbs as "may", "will", "should" or "would", or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. For these statements, we claim the protection of the safe harbour for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. The risks and uncertainties referred to above include, but are not limited to: variability of operating results among periods; inability to retain or grow our business due to execution problems resulting from significant headcount reductions, plant closures and product transfer associated with major restructuring activities; the effects of price competition and other business and competitive factors generally affecting the EMS industry; the challenges of effectively managing our operations during uncertain economic conditions; our dependence on a limited number of customers; our dependence on industries affected by rapid technological change; the challenge of responding to lower-than-expected customer demand; our ability to successfully manage our international operations; and delays in the delivery and/or general availability of various components used in the manufacturing process. These and other risks and uncertainties and factors are discussed in the Company's various public filings at [www.sedar.com](http://www.sedar.com) and [www.sec.gov](http://www.sec.gov), including our Form 20-F and subsequent reports on Form 6-K filed with the Securities and Exchange Commission. Except as required by applicable law, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

# Company Overview



- HQ: Toronto, Canada
- Listed on TSX-V (VPT) & OTCQB (VPTDF)
- Patented technology

# ***Product Evolution***



**VMS 1.0**



**VMS+ 2.0**



**VMS+ 3.0**

# Goals & Clinical Outcomes



TO BE THE **PREMIER**  
**CARDIAC IMAGING**  
TOOL



HEART DISEASE IS THE  
**LEADING CAUSE** OF  
DEATH FOR BOTH  
MEN AND WOMEN  
WORLDWIDE




**\$200 BILLION** SPENT  
ON CARDIOVASCULAR  
DISEASE IN US  
ANNUALLY




CARDIAC  
MEASUREMENTS **ARE**  
**CRITICAL TO ASSESS**  
HEART DISEASE


# *Cardiac Diseases*




Rastelli repair




Pulmonary  
hypertension




Ebstein's  
anomaly



Double Outlet Right  
Ventricle



Tetralogy of  
Fallot (TOF)



RV to PA  
conduit





# ***Problem***

- Standard Echocardiograms (Echos) have physical limitations
- Difficult to measure the Right Ventricle (RV) with a standard Echo
- Standard of care is to refer to MRI for both adults and children

# ***Solution = Ventripoint VMS+ 3.0 System***



- Connects to standard Echo, the most common cardiac imaging technology globally
- Measures the whole heart and RV
- Knowledge Based Reconstruction (KBR) of 3D images equivalent to MRI




# ***CUSTOMERS***

- 1. CARDIOLOGISTS** – Confidence in Echo images and RV
- 2. SONOGRAPHERS** - NOW it integrates into workflow.  
Captures images from poor quality Echo images
- 3. HOSPITAL ADMINISTRATORS** - Revenue and Cost Savings

**CPT 76377 FEE CODE = REVENUE**  
**&**  
**EFFECTIVE USE OF MRI = COST SAVINGS**

# *The Market*



***CPT 76377 = \$80***

76377 - CPT® Code in category: 3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging, ultrasound, or other tomographic modality

# *Revenue Projections*

	Year 1	Year 2	Year 3
Systems	100	200	300
Systems Revenue	\$5M	\$10M	\$15M
Annual Software Subscription	\$500K	\$1.5M	\$3M
SaMD/Unit (400X\$20)	\$800K	\$2.4M	\$4.8M
<b>Total</b>	<b>\$6.3M</b>	<b>\$14M</b>	<b>\$18M</b>

# *Comparables*



\$100M

**mindray**

ZONARE

\$104M



\$250M

# ***Stock Promotion***

- FDA Announcement
- Leading hospitals in Canada and US using VMS+ 3.0
- Engaging IR companies to create market awareness
- New website launch


# *AI as defined by the FDA*

AI, and specifically Machine Learning, are techniques used to design and train software algorithms to learn from and act on data. These AI/ML-based software, when intended to treat, diagnose, cure, mitigate, or prevent disease or other conditions, are medical devices under the FD&C Act, and called “Software as a Medical Device” (SaMD) by FDA



# ***Knowledge Based Reconstruction (KBR) Technology***

KBR is an AI software made from an extensive cardiac MRI database covering a wide array of clinical conditions and cardiac shapes




Right Ventricle


- Volumes
- Ejection fraction
- 3D surface visualization

# Volume and Ejection Fraction Calculations

## 3D view of Right Ventricle showing anatomical landmarks



# ***Combined Volumetric Measurements 3D view of RV and LV showing End Systolic and End Diastolic***



# Current Users & Publications

**St. Michael's**  
Inspired Care. Inspiring Science.



THE UNIVERSITY OF TEXAS  
**MDAnderson**  
~~Cancer~~ Center

**SickKids**

Alberta **Children's** Hospital

**Mazankowski Alberta Heart Institute**


Ventripoint's KBR technology in over 60 publications

For a listing of notable publications:


<https://www.ventripoint.com/clinical-research.html>

# ***Advantages of Ventripoint Patented VMS+ System***

- **Confidence** in volumetric measurements of the heart from standard 2D Echo images
- **All 4 chambers** with ability for measurements on technically difficult patients
- **Timely** & fits within a normal Echo lab workflow
- **Reproducible** and operator independent
- **Cost-effective** solution to MRI
- **Vendor Neutral** - Can be used with any existing ultrasound machine
- **CPT Code** in the U.S. - 76377



**Ventripoint**  
Diagnostics Ltd.



2 Sheppard Avenue East, Suite 605  
Toronto, Ontario  
Canada M2N 5Y7

Phone: +1 (416) 848-4156

Email: [jleushner@ventripoint.com](mailto:jleushner@ventripoint.com)

Website: [www.ventripoint.com](http://www.ventripoint.com)



**Ventripoint**  
Diagnostics Ltd.